Patel AD, Ravichandran S, Kheterpal M, et al. - Use of HHIT (hedgehog inhibitor therapy) ± AT (adjunctive therapy) for treating locally advanced, unresectable basal cell carcinomas (laBCCs) in a single institution resulted in 10/14 laBCCs (71%) with complete responses (CRs) without recurrence and 4/14 laBCCs (29%) with partial responses (PRs) over median follow-up of 15.5 months.

• A retrospective review at Duke University from 11/01/2007 through 5/20/2020.

• Fourteen laBCCs were found in 13 patients.

• Sonidegib (n = 10, 71%) or vismodegib (n = 4, 29%) was given to treat laBCCs for a median (IQR) of 9.4 (9.3) or 9.8 (8.5) months, respectively.

• The median (IQR) follow-up time from HHIT start was 15.5 (8.7) months.

• HHIT alone was used to manage nine laBCCs (64%), of which five (36%) showed CR, four (29%) achieved PR, and five (36%) demonstrated CR with combined HHIT and AT post-HHIT.

• HHIT-induced adverse events occurred in nine patients (69%), most commonly ageusia/dysgeusia, muscle spasms, and alopecia.